Page 115 - Human Use News Today

Positive CHMP opinion recommends extending use of Adtralza (tralokinumab) to adolescents (12-17 years old) in the European Union (EU) Recommendation supported by data from the Phase 3 ECZTRA

/PRNewswire/ -- The "Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type, Therapeutic Conditions, Route of...

STOCKHOLM, Sept. 16, 2022 /PRNewswire/ -- Sobi and ADC Therapeutics SA today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted

If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the

Therapy has been developed for the prevention of disease in infants - News - PharmaTimes

FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced Friday that its unit Kite's CAR T-cell Therapy Yescarta (axicabtagene ciloleucel) has received a positive opinion from the European

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency (EMA) has recommended converting

16.09.2022 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to extend the indication of Veklury (remdesivir) for the treatment ... Seite 1

What could be the first vaccine for infants to prevent illness caused by respiratory syncytial virus (RSV) has received a nod from the European Medicines Agency.